| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
2,301 |
1,891 |
$177K |
| 8888888 |
Internal/system code - not a standard HCPCS code |
137 |
91 |
$101K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
1,519 |
1,373 |
$43K |
| 80306 |
|
359 |
329 |
$43K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
568 |
492 |
$32K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
224 |
210 |
$28K |
| 80050 |
General health panel |
116 |
111 |
$22K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
372 |
345 |
$16K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
728 |
625 |
$12K |
| 80053 |
Comprehensive metabolic panel |
2,452 |
2,036 |
$9K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
78 |
67 |
$8K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
160 |
152 |
$5K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
258 |
219 |
$4K |
| 81001 |
|
558 |
502 |
$4K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
29 |
26 |
$3K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
80 |
68 |
$3K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
203 |
180 |
$2K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
328 |
280 |
$2K |
| 71045 |
Radiologic examination, chest; single view |
145 |
134 |
$1K |
| 84443 |
Thyroid stimulating hormone (TSH) |
113 |
101 |
$1K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
109 |
98 |
$1K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
17 |
17 |
$923.92 |
| 84702 |
|
30 |
26 |
$750.72 |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
286 |
260 |
$586.52 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
327 |
276 |
$490.63 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
62 |
55 |
$488.51 |
| 84439 |
|
42 |
39 |
$330.10 |
| 36415 |
Collection of venous blood by venipuncture |
18 |
15 |
$147.04 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
19 |
17 |
$145.63 |
| 83690 |
|
205 |
185 |
$96.82 |
| 80061 |
Lipid panel |
13 |
12 |
$74.10 |
| 86140 |
|
1,158 |
990 |
$32.09 |
| 83605 |
|
287 |
248 |
$11.30 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
356 |
324 |
$0.00 |
| 84484 |
|
56 |
51 |
$0.00 |
| 85379 |
|
29 |
27 |
$0.00 |
| 85651 |
|
62 |
51 |
$0.00 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
94 |
84 |
$0.00 |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
13 |
13 |
$0.00 |